AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17694201 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise (3M Espe) sealant
Number of subjects: 0
Study 17694201 — intervention group
Group type: COMPARATOR
Intervention: Prisma Shield (Caulk/Dentsply) sealant
Number of subjects: 0
Study 15389416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy-dense salad (0.33 kcal/g) small portion (150 g)
Number of subjects: 42
Study 15389416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy-dense salad (0.33 kcal/g) large portion (300 g)
Number of subjects: 42
Study 15389416 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy-dense salad (1.33 kcal/g) small portion (150 g)
Number of subjects: 42
Study 15389416 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy-dense salad (1.33 kcal/g) large portion (300 g)
Number of subjects: 42
Study 15389416 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion of lower-energy-dense salad (compared to a high-energy-dense salad with the same calories)
Number of subjects: 42
Study 15389416 — intervention group
Group type: COMPARATOR
Intervention: No salad (control condition)
Number of subjects: 42
Study 12090907 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril monotherapy (20 mg daily for 30 months)
Number of subjects: 66
Study 12090907 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide and hydralazine combination
Number of subjects: 66
Study 9520174 — intervention group
Group type: EXPERIMENTAL
Intervention: COL‐1492 gel
Number of subjects: 534
Study 9520174 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 534
Study 9520174 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 534
Study 8061724 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (11.1 mumol/kg/min) + Amino acids infusion (3.33 mg/kg/min for last 4 hours)
Number of subjects: 10
Study 8061724 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion (11.1 mumol/kg/min) + Lipids infusion (Lipovenös, 10% 10 ml/min for 7.5 h) + Amino acids infusion (for last 4 hours)
Number of subjects: 10
Study 8061724 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion (11.1 mumol/kg/min) + Lipids infusion (10% 10 ml/min) + Amino acids infusion (for last 4 hours)
Number of subjects: 10
Study 2509153 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 (polyglycosides of Tripterygium wilfodii hook F)
Number of subjects: 70
Study 959765 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal acidification
Number of subjects: 18
Study 959765 — intervention group
Group type: COMPARATOR
Intervention: Exogenous hormones (secretin and CCK)
Number of subjects: 18
Study 31982359 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin
Number of subjects: 120
Study 31982359 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin
Number of subjects: 120
Study 31982359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31288827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar coagulation
Number of subjects: 84
Study 31288827 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic suture
Number of subjects: 84
Study 31288827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic matrix
Number of subjects: 84
Study 28719287 — intervention group
Group type: EXPERIMENTAL
Intervention: DPIV formulations (1 or 4 μg with aluminum hydroxide or 1 μg with AS01E or AS03B)
Number of subjects: 100
Study 28719287 — intervention group
Group type: EXPERIMENTAL
Intervention: DPIV formulations
Number of subjects: 100
Study 28719287 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 26553086 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg/PO/bed time)
Number of subjects: 27
Study 26553086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24119468 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR-radiated therapy (40-minute radiation at the major lesion site or anastomosed site three times a week)
Number of subjects: 216
Study 24119468 — intervention group
Group type: COMPARATOR
Intervention: Control group (free-radiated usual therapy)
Number of subjects: 216
Study 24119468 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR-radiated therapy
Number of subjects: 216
Study 21504407 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Walking Test (FWT)
Number of subjects: 56
Study 19793367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (group I, n = 32)
Number of subjects: 64
Study 19793367 — intervention group
Group type: COMPARATOR
Intervention: Control (group II, n = 32)
Number of subjects: 64
Study 17526179 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint drug-finger pressing (ADFP) on Ganshu (BL18), Danshu (BL19), Weishu (BL21), and Pishu (BL20) acupoints, 15 min each time, twice per day for 3 weeks.
Number of subjects: 80
Study 17526179 — intervention group
Group type: COMPARATOR
Intervention: Acid-inhibitory and gastrokinetic drugs (omeprazole 20 mg once every 12 hours and cisapride 10 mg thrice daily before meals) for 3 weeks.
Number of subjects: 80
Study 17526179 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ADFP and control)
Number of subjects: 80
Study 15513716 — intervention group
Group type: EXPERIMENTAL
Intervention: Key size of 20 mm
Number of subjects: 20
Study 15513716 — intervention group
Group type: COMPARATOR
Intervention: Key sizes of 10, 15 mm
Number of subjects: 20
Study 15513716 — intervention group
Group type: COMPARATOR
Intervention: Key size of 25 mm
Number of subjects: 20
Study 11487144 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% EDTA/NaOCl
Number of subjects: 50
Study 11487144 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% polyacrylic acid
Number of subjects: 50
Study 11487144 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric acid
Number of subjects: 50
Study 11487144 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% citric acid
Number of subjects: 50
Study 11487144 — intervention group
Group type: COMPARATOR
Intervention: 5.25% NaOCl
Number of subjects: 50
Study 9663911 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring for 2 weeks (6 work days, duplicate measurements, twice daily)
Number of subjects: 189
Study 7893593 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine bicycle ergometry
Number of subjects: 0
Study 7893593 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 1-adrenoceptor antagonism
Number of subjects: 0
Study 7893593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergometric rise of HR
Number of subjects: 0
Study 2316416 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic beer
Number of subjects: 0
Study 334490 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 48
Study 334490 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 48
Study 31876052 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Echinacea angustifolia root extract twice daily for 7 days
Number of subjects: 0
Study 31876052 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets twice daily for 7 days
Number of subjects: 0
Study 31389880 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand surgery (carpal tunnel release, trigger finger release, ganglion or retinacular cyst excision, de Quervain's release, or soft‐tissue mass excision)
Number of subjects: 430965
Study 31389880 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical antibiotic prophylaxis before hand surgery
Number of subjects: 430965
Study 31389880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hand surgery)
Number of subjects: 430965
Study 28100522 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 5499
Study 25045795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathejell lubricant with lidocaine 12.5g administered immediately before cystoscopy
Number of subjects: 242
Study 25045795 — intervention group
Group type: COMPARATOR
Intervention: Cathejell lubricant with lidocaine 12.5g maintained for 5 minutes before cystoscopy
Number of subjects: 242
Study 22580433 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery pen (ECP)
Number of subjects: 80
Study 22580433 — intervention group
Group type: COMPARATOR
Intervention: Nylon 10‐0 sutures
Number of subjects: 80
Study 21644803 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook profiles showing older peers drinking
Number of subjects: 189
Study 21644803 — intervention group
Group type: COMPARATOR
Intervention: Facebook profiles showing older peers not drinking
Number of subjects: 189
Study 19567857 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilisation in external rotation (15 to 20 degrees)
Number of subjects: 51
Study 19567857 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation in internal rotation (traditional brace)
Number of subjects: 51
Study 17327338 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg q.d. and 60 mg b.i.d.
Number of subjects: 0
Study 17327338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17327338 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 16083193 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplement (5 g with orange solution 15 g, twice per day for 7 days)
Number of subjects: 38
Study 16083193 — intervention group
Group type: COMPARATOR
Intervention: Control group (orange solution only)
Number of subjects: 38
Study 11109037 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin clip technique
Number of subjects: 162
Study 11109037 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture technique
Number of subjects: 162
Study 8922007 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine (SQL) pretreatment
Number of subjects: 110
Study 8922007 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (Control)
Number of subjects: 110
Study 1550365 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photochemotherapy
Number of subjects: 79
Study 1550365 — intervention group
Group type: COMPARATOR
Intervention: D‐penicillamine (maximum dose of 750 mg/d)
Number of subjects: 79
Study 1550365 — intervention group
Group type: COMPARATOR
Intervention: D‐penicillamine
Number of subjects: 79
Study 2931846 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrysanol (1.5 ml of a 5% solution)
Number of subjects: 50
Study 2931846 — intervention group
Group type: COMPARATOR
Intervention: Myochrysine (50 mg, 25 mg metallic gold once a week)
Number of subjects: 50
Study 30964227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 30
Study 30964227 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fractional CO2 laser and PRP
Number of subjects: 30
Study 30564154 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPaCT psychosocial health intervention
Number of subjects: 293
Study 30564154 — intervention group
Group type: COMPARATOR
Intervention: Eligible comparator population
Number of subjects: 293
Study 28169258 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (PDT) using 810 nm diode laser and Indocyanine green as photosensitizer
Number of subjects: 0
Study 28169258 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root‐planing (SRP)
Number of subjects: 0
Study 25453731 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitors) ± ezetimibe
Number of subjects: 0
Study 22421716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing thrice a day for 1 hour each time starting 6 hours after surgery until the passage of first flatus
Number of subjects: 100
Study 22421716 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative treatment
Number of subjects: 100
Study 20533219 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination diet (soy formula or casein hydrolysate)
Number of subjects: 92
Study 20533219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no elimination diet)
Number of subjects: 92
Study 17617906 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA followed by PDA survey
Number of subjects: 152
Study 17617906 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA followed by paper survey
Number of subjects: 152
Study 17617906 — intervention group
Group type: EXPERIMENTAL
Intervention: paper followed by PDA survey
Number of subjects: 152
Study 16301881 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic depression after ECT
Number of subjects: 59
Study 16301881 — intervention group
Group type: COMPARATOR
Intervention: Nonpsychotic depression after ECT
Number of subjects: 59
Study 12002352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin (5 mg/30 ml three times daily)
Number of subjects: 9
Study 12002352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9813559 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (nitric oxide synthase inhibitor)
Number of subjects: 12
Study 9813559 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (endothelium independent vasodilator)
Number of subjects: 12
Study 9813559 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin (endothelium dependent vasodilator)
Number of subjects: 12
Study 7653804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min during CPB (normothermic)
Number of subjects: 36
Study 7653804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min during CPB (hypothermic)
Number of subjects: 36
Study 7653804 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 50 micrograms/kg as a rapid infusion over 10 min (nonbypass group)
Number of subjects: 36
Study 7653804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (normothermic CPB)
Number of subjects: 36
Study 7653804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (hypothermic CPB)
Number of subjects: 36
Study 7653804 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil (nonbypass group)
Number of subjects: 36
Study 7653804 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (normothermic vs hypothermic CPB)
Number of subjects: 36
Study 2496420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 6
Study 2496420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (4 mg)
Number of subjects: 6
Study 2496420 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum (0 mg)
Number of subjects: 6
Study 828982 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I: saline solution (1000‐1500 ml), glucose (100‐150 g), and amino acids (15‐30 g) per day
Number of subjects: 44
Study 828982 — intervention group
Group type: COMPARATOR
Intervention: Group II: 40‐50 Cal/kg per day (dextrose about 15 g/kg per day), about 2 g of amino acids/kg/day and about 40‐50 ml water/kg/day
Number of subjects: 44
Study 828982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperalimentation (both treatments sequentially)
Number of subjects: 44
Study 828982 — intervention group
Group type: COMPARATOR
Intervention: Both groups (comparison)
Number of subjects: 44
Study 31077251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Rank Method (MRM)
Number of subjects: 421
Study 31077251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary Least Squares (OLS)
Number of subjects: 421
Study 31077251 — intervention group
Group type: EXPERIMENTAL
Intervention: Equi-percentile Method (EPM)
Number of subjects: 421
Study 29154057 — intervention group
Group type: EXPERIMENTAL
Intervention: Far-infrared ray (FIR) patches applied to 98 MTrPs for 24 hours in the intervention group (61 patients)
Number of subjects: 125
Study 29154057 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches applied to 91 MTrPs in the control group (57 patients)
Number of subjects: 125
Study 24458801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (RSV) 10 mg/d
Number of subjects: 262
Study 24458801 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (RSV) 10 mg/d plus Ezetimibe (EZT) 10 mg/d
Number of subjects: 262
Study 24458801 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 262
Study 24458801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (RSV) 10 mg/d and Ezetimibe (EZT) 10 mg/d
Number of subjects: 262
Study 23619829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block anesthesia
Number of subjects: 33
Study 23619829 — intervention group
Group type: COMPARATOR
Intervention: Conventional spinal anesthesia
Number of subjects: 33
Study 23619829 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 21330640 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (320 mg daily)
Number of subjects: 79
Study 21330640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 19387176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (16 mg/kg) administered 3 min after rocuronium (1.2 mg/kg)
Number of subjects: 115
Study 19387176 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg/kg)
Number of subjects: 115
Study 17291177 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of an inert placebo described as a suspected environmental toxin
Number of subjects: 0
Study 17291177 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of a female confederate inhaling the substance and displaying symptoms
Number of subjects: 0
Study 17291177 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in reported symptoms
Number of subjects: 0
Study 14699004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ramipril (10 mg/d) and atorvastatin (40 mg/d)
Number of subjects: 45
Study 14699004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10877131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 28
Study 10877131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9060538 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical second look (SSL)
Number of subjects: 102
Study 9060538 — intervention group
Group type: COMPARATOR
Intervention: No surgical second look (follow-up evaluation only)
Number of subjects: 102
Study 8445234 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon with or without prednisone priming
Number of subjects: 272
Study 8445234 — intervention group
Group type: COMPARATOR
Intervention: Control (negative for hepatitis B virus deoxyribonucleic acid)
Number of subjects: 272
Study 8445234 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon with or without steroid priming
Number of subjects: 272
Study 3725503 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard magnesium-aluminum hydroxide antacids at a dose of 0.5 mL/kg per dose
Number of subjects: 0
Study 30630801 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy integrated with neoadjuvant chemotherapy
Number of subjects: 68
Study 30630801 — intervention group
Group type: COMPARATOR
Intervention: Radical resection of breast cancer
Number of subjects: 68
Study 28667881 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy
Number of subjects: 18
Study 28667881 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (wait-list group)
Number of subjects: 18
Study 26209857 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2mg/d)
Number of subjects: 29
Study 26209857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 24565125 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (stylet replacement before needle removal)
Number of subjects: 630
Study 24565125 — intervention group
Group type: COMPARATOR
Intervention: Group B (needle removal without stylet replacement)
Number of subjects: 630
Study 21148135 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilation
Number of subjects: 201
Study 21148135 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary rehabilitation
Number of subjects: 201
Study 18507868 — intervention group
Group type: EXPERIMENTAL
Intervention: BB therapy with thrice-daily insulin aspart and once-daily basal insulin (BB group)
Number of subjects: 42
Study 18507868 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with twice-daily biphasic insulin analogue (30 Mix group)
Number of subjects: 42
Study 17320017 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing interventions directed to the patient and environment for maintaining time-space orientation and cognitive functions
Number of subjects: 48
Study 17320017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study 12663006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal hinge LASIK
Number of subjects: 30
Study 12663006 — intervention group
Group type: COMPARATOR
Intervention: Superior hinge LASIK
Number of subjects: 30
Study 12663006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 10379622 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher nicotine yield cigarettes (1.1 mg nicotine yield)
Number of subjects: 0
Study 10379622 — intervention group
Group type: COMPARATOR
Intervention: Very low nicotine yield cigarette (0.05 mg nicotine yield)
Number of subjects: 0
Study 8950781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC) with low estrogen formulations containing norgestimate or gestodene
Number of subjects: 0
Study 1850722 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose chemotherapy (60 mg/m2 doxorubicin and 500 mg/m2 5-fluorouracil every 3 weeks)
Number of subjects: 0
Study 1850722 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I antiferritin administration every 8 weeks
Number of subjects: 0
Study 1850722 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I antiferritin administration
Number of subjects: 0
Study 6890374 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine (300 micrograms)
Number of subjects: 6
Study 6890374 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (300 micrograms)
Number of subjects: 6
Study 30644774 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP), 10 sessions
Number of subjects: 830
Study 30644774 — intervention group
Group type: COMPARATOR
Intervention: Active 2‐session comparison condition (control)
Number of subjects: 830